FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...
WEHT Evansville on MSN2h
Gov. Holcomb to lead U.S. delegation to Greece
Governor Eric J. Holcomb says he will lead an international trip to Greece next week at the invitation of the Council of ...
Novo and Lilly contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...
WeightWatchers stock soars, but its cheap Wegovy knockoff 'is not a sustainable long-term business model'
WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...
Wegovy maker Novo Nordisk bets big on talent, AI partnerships in India
Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...
GlobalData on MSN7h
XtalPi’s AI biologics discovery platform licensed to Janssen Biotech
XtalPi, an AI drug discovery company and subsidiary of Ailux Biologics, has entered a licensing agreement with Janssen ...
STAT15h
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Pharmaceutical Technology on MSN12h
KeyBioscience and Eli Lilly extend partnership for obesity treatments
KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated ...
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
Ibj.com6h
Why Lilly is pouring billions into LEAP
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...
FiercePharma9h
Lilly's manufacturing splurge continues with $200M expansion in China
Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...